PMD Solutions, an industry-leading medical technology company based in Cork, Ireland, today announced the issuance of Japanese Patent No. 6401718 Titled “A Method and Device for Respiratory Monitoring” issued September 14, 2018.
PMD’s premier product, RespiraSense™ (Breathing Rate Monitoring), has already received regulatory approvals for the sales and marketing of the device across the European Union. This milestone now enables PMD to establish a wider presence in countries on other continents.
“RespiraSense™ is a revolution in the early identification of patient deterioration. The granting of RespiraSense™’s patent will enable PMD Solutions to invest further in the global commercialisation of our best-in-class innovation. Through working with leading university hospitals and national health authorities, PMD is set to establish a new standard of care for continuous breathing rate monitoring by 2020” says Myles Murray, CEO of PMD Solutions.
Respiratory rate’s value has been significantly published for the last 10 years, and yet manual counting breaths remain the global industry standard. Spontaneous breathing is challenging to measure accurately, however, this challenge has become PMD’s advantage as a result of its novel wearable respiratory sensor technology.
Since 2016, PMD Solutions has been working with a network of thought leaders in the fields of early warning scoring, vital signs, and improvement in hospital systems. In 2017 PMD announced research partnerships with European Centres of Excellence in Denmark, Wales and England and together they continue to demonstrate the value of respiratory rate and the clinical and economic impact it has on patient care.
Murray adds, “RespiraSense™ works with centres of excellence across Europe and world-leading opinion leaders, globally, in the field of vital signs and patient deterioration. With the increasing pressures put onto healthcare institutions, prevention is the word when it comes to addressing both financial savings without compromising patient safety.”
Japan’s medical device market, the third largest in the world, ahead of China and Germany, imports 40% of its requirements. The Japanese government spends 10% of GDP each year on healthcare, making it the third largest globally.
The grant of that patent provides further recognition of the quality of the innovation being carried out by the team at PMD Solutions.